2326521-71-3
- Product Name：Adagrasib
- Molecular Formula：C32H35ClFN7O2
- Purity：99%
- Molecular Weight：604.1
Product Details:
CasNo： 2326521-71-3
Molecular Formula： C32H35ClFN7O2
Chinese Manufacturer Supply Adagrasib,Hot Sale 2326521-71-3 Cheap Price
- Molecular Formula:C32H35ClFN7O2
- Molecular Weight:604.1
- Melting Point:From > 262 mg/mL to < 0.010 mg/mL
Adagrasib(Cas 2326521-71-3) Usage
|
Description |
Adagrasib, marketed under the brand name Krazati, is a medication used to treat certain types of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It is specifically designed to inhibit the action of the KRAS G12C mutant protein, which is present in some cancer types and is responsible for promoting the uncontrolled multiplication of cancer cells. Adagrasib is a highly selective small-molecule inhibitor that targets this mutation, disrupting the growth of cancer cells and leading to their destruction. Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. Our existing advantages have led to our in-depth services for the R&D of small molecule drug discovery. At present, Huarong Pharm has successfully delivered innovative R&D products and services to more than 3,000 partners across the world. Our goal is to become a world-class leading company to support life science innovation and manufacturing. |
|
Uses |
Adagrasib is taken orally, usually twice daily, and can be administered with or without food. It is typically prescribed to adults with NSCLC or CRC who have undergone at least one prior treatment and whose cancer has either spread (metastasized) or cannot be removed surgically. Adagrasib blocks the KRAS G12C mutant protein, halting the signals that instruct cancer cells to proliferate. This targeted mechanism makes it an effective treatment for cancers driven by this specific mutation. |
| FDA Approval | In 2022, Adagrasib received accelerated approval from the FDA for the treatment of locally advanced or metastatic NSCLC in patients who have previously received at least one other treatment. |
| Clinical Efficacy | In clinical trials, specifically phase I/IB studies, Adagrasib (MRTX849) demonstrated antitumor activity in patients with advanced solid tumors, including NSCLC and CRC, harboring the KRAS G12C mutation. The recommended dosage is 600 mg twice daily, and the treatment has shown promising results in halting tumor growth. |
2326521-71-3 Relevant articles
KRYSTAL-1: updated safety and efficacy data with adagrasib (MRTX849) in NSCLC with KRASG12C mutation from a phase 1/2 study
Pasi A. Jänne1; Igor I. Rybkin2; Alexander Spira3; Gregory J. Riely4; Kyriakos P. Papadopoulos5; Joshua Sabari6; Melissa L. Johnson7; Rebecca S. Heist8; Lyudmila Bazhenova9, Minal Barve10, Jose M. Pacheco11; Ticiana A. Leal12; Karen Velastegui13; Cornelius Cilliers13; Peter Olson13; James G. Christensen13; Thian Kheoh13; Richard C. Chao13; Sai-Hong Ignatius Ou14
32nd EORTC-NCI-AACR Symposium, October 24-25, 2020
Previously reported data from Phase 1 demonstrated clinical activity with adagrasib (MRTX849) in patients with pretreated KRASG12C NSCLC and CRC • 600 mg BID was chosen as …
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
P.A. Jänne I.I. Rybkin A.I. Spira T. Kheoh R.C. Chao S.H.I. Ou
SUNDAY, 25 OCTOBER 2020 15:45–17:15: PLENARY SESSION 2: LATE BREAKING AND BEST
Adagrasib, an investigational agent, is a potent, covalent inhibitor of KRAS G12C that irreversibly and selectively binds to and locks KRAS G12C in its inactive state. Adagrasib was optimized to exhibit a long half-life in order to achieve durable and continuous KRAS inhibition, which is postulated to prevent feedback loops and lead to deep and durable antitumor activity.
Relevant Products
-
MilvexianCAS：1802425-99-5
-
ApalutamideCAS：956104-40-8
-
Eribulin MesylateCAS：441045-17-6
